Shares of IOVA are trading -7% lower today. A quick overview:

Shares of Iovance Biotherapeutics Inc (IOVA) are trading -7% lower at a price of $6.62 at the time of this writing. While it's generally been a cheery day for this part of the market, the company is trailing behind it's peers in the Health Care sector.

-Iovance Biotherapeutics, Inc. (IOVA) has received feedback from the Food and Drug Administration (FDA) on the rolling Biologics License Application for Lifileucel, an investigational drug for melanoma
-The FDA has requested additional data
-Shares of IOVANCE are down more than 14% as a result

Iovance Biotherapeutics Inc has been trading between a 52-week high of $20.6 and a 52-week low of $5.42. The stock has a market cap of $1.04 Billion.

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient.

Headlines

Why Iovance Biotherapeutics Is Crashing Today
The Motley Fool 11-18-22

Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
Benzinga 11-18-22

Iovance''s stock is down after receiving FDA feedback on application for new melanoma drug
MarketWatch 11-18-22

Iovance Biotherapeutics Tanks as FDA Requests More Data for Lifileuel
TipRanks 11-18-22

Williams-Sonoma, Farfetch, Iovance Biotherapeutics among premarket losers'' pack
Seeking Alpha 11-18-22